GH Stock Forecast & Price Target

Guardant Health, a leader in liquid-based cancer tests, has witnessed a notable increase in its two-year revenue compound annual growth rate (CAGR), rising to 28% from 2023 to 2025, driven by strong performance in colorectal cancer, breast cancer, and other applications, as well as the expansion of its monitoring capabilities. The company's revenue guidance for the Shield test exceeded estimates, contributing to an overall increase in its annual revenue outlook, with expectations for approximately 31% year-over-year growth in 2025. Furthermore, Guardant Health's stock performance has been robust, with shares up 136% year-to-date and an additional 20% in after-hours trading, positioning the company for significant market cap growth, which may attract larger investment mandates.

Guardant Health's medium-term revenue guidance for its Shield product appears underwhelming, contributing to concerns about its future growth potential. An adjusted EBITDA loss of $45.5 million in 3Q25, combined with the need for cost efficiencies in research and development, raises questions about the sustainability of its financial performance amid ongoing operational challenges. Additionally, any adverse developments related to regulatory approval or reimbursement could further negatively impact the stock, indicating heightened risk for investors.